Session » 3S081: SLE – Clinical I: Clinical Trials (857–862)

Date: Sunday, November 10, 2019

Time: 2:30PM-4:00PM

Meeting: 2019 ACR/ARP Annual Meeting

2:30PM-4:00PM: Abstract Number: 858

Adverse Events of Special Interest, SLE Medication Utilization, Hospitalizations, and Organ Damage: Results from a Phase 4, Randomized, Double-Blind, Placebo-Controlled, 52-week Study of Belimumab in Adults with Active, Autoantibody-Positive SLE

2:30PM-4:00PM: Abstract Number: 861

Cutaneous Lupus Erythematosus Disease Area & Severity Index (CLASI) Demonstrates Thresholds for Detection of Treatment Response in a Phase-2, Placebo-Controlled Trial of Ustekinumab in SLE

2:30PM-4:00PM: Abstract Number: 860

Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations

2:30PM-4:00PM: Abstract Number: 862

First Use of Cenerimod, a Selective sphingosine-1-phosphate 1 (S1P1) Receptor Modulator, for the Treatment of Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase II, Proof-of-Concept Study

2:30PM-4:00PM: Abstract Number: 859

Long-term Outcome of a Randomized Controlled Trial Comparing Tacrolimus with Mycophenolate Mofetil as Induction Therapy of Severe Lupus Nephritis

2:30PM-4:00PM: Abstract Number: 857

Mesenchymal Stem Cell Therapy Induces FLT3L and CD1c+ Dendritic Cells in Systemic Lupus Erythematosus Patients

« View all sessions from this meeting